Extended indication Nephrotic dysorder
Therapeutic value No judgement
Registration phase Unknown

Product

Active substance Levamisole (hydrochloride)
Domain Metabolism and Endocrinology
Main indication Metabolic diseases
Extended indication Nephrotic dysorder
Proprietary name Elmisol
Manufacturer Ace
Mechanism of action Unknown
Route of administration Unknown
Therapeutical formulation Unknown
Budgetting framework Unknown
Additional remarks Registratieaanvraag ingetrokken in juni 2017. Reden intrekken registratieaanvraag: "...the company stated that it was withdrawing its application because there were concerns about the main study which would prevent its use to support the application." Janssen heeft aangegeven dat het voornemens is een nieuwe aanvraag in te dienen en dat er nieuwe studies gestart zijn.

Registration

Registration route Unknown
Type of trajectory Unknown
Particularity Unknown
ATMP Unknown
Orphan drug Unknown
Registration phase Unknown

Therapeutic value

Therapeutic value No judgement

This assessment does not indicate any potential inclusion in the package.

Expected patient volume per year

Patient volume

Market share is generally not included unless otherwise stated.

Expected cost per patient per year

Potential total cost per year

Off label use

Off label use Unknown

Indication extension

Indication extensions Unknown

Other information